ArticleThe Lancet regional health. Western Pacific2022

Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study.

Dr Nick Scott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.